Given the success of immune profiling in MM pilot studies, we aimed to utilise the same approach specifically in patients with relapse or refractory CLL treated with BTK inhibitors, in this instance ibrutinib, to identify immune profiles associated with future infection risk as proof of concept in this patient group. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.